CIK細(xì)胞配合二線化療治療晚期肺癌的療效分析

王春娜

【摘要】 目的 分析細(xì)胞因子誘導(dǎo)殺傷（CIK）細(xì)胞配合二線化療治療晚期肺癌患者的臨床效果。

方法 104例晚期肺癌患者， 隨機(jī)分成實(shí)驗(yàn)組和對(duì)照組， 每組52例。對(duì)照組患者采用二線化療方法進(jìn)行治療， 實(shí)驗(yàn)組患者在對(duì)照組基礎(chǔ)上使用CIK細(xì)胞進(jìn)行聯(lián)合治療。比較兩組患者治療前后T細(xì)胞群改善情況及不良反應(yīng)發(fā)生情況。結(jié)果 治療前， 兩組患者CD3+、CD56+、CD4+、CD4+/CD8+比較差異均無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）；治療后， 實(shí)驗(yàn)組患者CD3+、CD56+、CD4+、CD4+/CD8+均高于本組治療前， 且實(shí)驗(yàn)組高于對(duì)照組， 差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。實(shí)驗(yàn)組患者白細(xì)胞減少發(fā)生率為11.5%、胃腸不適發(fā)生率為19.2%、血紅蛋白降低發(fā)生率為11.5%， 均低于對(duì)照組的28.8%、38.5%、28.8%， 差異均具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 采用CIK細(xì)胞配合二線化療治療晚期肺癌患者， 療效顯著， 安全性高， 值得臨床大力推廣。

【關(guān)鍵詞】 肺癌；化療；細(xì)胞因子誘導(dǎo)殺傷細(xì)胞

DOI：10.14163/j.cnki.11-5547/r.2018.02.001

Analysis of the efficacy of CIK cells combined with second-line chemotherapy in the treatment of advanced lung cancer WANG Chun-na. Department of Respiratory Medicine， Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital， Baotou 014000， China

【Abstract】 Objective To analyze the clinical effect of cytokine induced killer （CIK） cells combined with second-line chemotherapy for the treatment of advanced lung cancer patients. Methods A total of 104 advanced lung cancer patients were randomly divided into experimental group and control group， with 52 cases in each group. The control group received second-line chemotherapy， and the experimental group received combined therapy with CIK cell on the basis of the control group. Comparison were made on improvement of T cell group before and after treatment and the occurrence of adverse reactions between two groups. Results Before treatment， both groups had no statistically significant difference in CD3+， CD56+， CD4+ and CD4+/CD8+ （P>0.05）. After treatment， the experimental group had higher CD3+， CD56+， CD4+ and CD4+/CD8+ than before treatment， and the experimental group was higher than the control group. Their difference was statistically significant （P<0.05）. The experimental group had incidence of leukocyte reduction as 11.5%， incidence of gastrointestinal discomfort as 19.2% and incidence of hemoglobin reduction as 11.5%， which were all lower than 28.8%， 38.5% and 28.8% in the control group， and their difference was statistically significant （P<0.05）. Conclusion Combination of CIK cells and second-line chemotherapy shows remarkable efficacy in the treatment of advanced lung cancer with high safety， and it is worthy of clinical promotion.

【Key words】 Lung cancer； Chemotherapy； Cytokine induced killer cells

肺癌為人體呼吸系統(tǒng)中肺組織部位腫瘤， 多見(jiàn)于長(zhǎng)期吸煙者或從事接觸有毒物質(zhì)的職業(yè)人群[1]。隨著環(huán)境污染的日益嚴(yán)重， 肺癌發(fā)病人群逐漸年輕化， 霧霾、煙塵等空氣污染物都是造成肺癌產(chǎn)生和發(fā)展的重要因素[2]。為此， 本院對(duì)收治的104例晚期肺癌患者進(jìn)行了臨床試驗(yàn)， 現(xiàn)報(bào)告如下。endprint

1 資料與方法

1. 1 一般資料 選擇2013年8月～2017年8月本院依據(jù)惡性腫瘤TNM分類法接收的104例肺癌晚期患者作為研究對(duì)象， 其中女40例， 男64例。將患者隨機(jī)分為對(duì)照組和實(shí)驗(yàn)組， 各52例。對(duì)照組中女21例， 男31例；年齡40～69歲， 平均年齡（43.5±8.5）歲；病程1～10個(gè)月， 平均病程（3.5±2.2）個(gè)月。

實(shí)驗(yàn)組女19例， 男33例；年齡39～71歲， 平均年齡（45.0±

8.5）歲；病程2～9個(gè)月， 平均病程（4.3±2.1）個(gè)月。兩組患者性別、年齡等一般資料比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）， 具有可比性。

1. 2 方法 經(jīng)醫(yī)院有關(guān)部門同意， 對(duì)照組患者采用二線化療方法進(jìn)行治療：將130 mg奧沙利鉑（浙江海正藥業(yè)股份有限公司， 國(guó)藥準(zhǔn)字H20093811）配制成250 ml的葡萄糖溶液， 于3～5 h內(nèi)緩慢靜脈滴注， 每隔3周用藥1次。實(shí)驗(yàn)組……